Solorank.ai
Login

Cached score snapshot

US.KVUE · Kenvue

110分制 55.3/110；5D動能v2 11/50；排序分 66.3/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 66.3/160
Main score 55.3/110
5D momentum v2 11/50
Rank #185
Setup grade F 33.1

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 33.1 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-07 08-03 08-18 09-01 09-14 $16.29$18.98$21.66 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.484 · anchors 120 -0.41% -2.34% / +1.97% 45% 5% Actual +0.89% · vs median +1.30% · inside 25-75 band
30D observation +1.05% -2.93% / +7.57% 60% 17.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 -0.38% -2.88% / +1.58% 46.3% 8.1% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-05-07 → 2026-09-14 · 235 archived points · 2 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 66.3
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 55.3/110 (觀望)
5D momentum v2 11/50 (弱)
Score with momentum v2 66.3/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 19.217
ma50 18.5624
close 19.01
prevClose 19.24
avgVolume20 19393269
volumeRatio 1.77
changePercent -1.2

Metrics snapshot

close 19.01
volume 34355370
changePercent -1.2

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 55.3/110
Main rating 觀望
5D momentum v2 11/50
Score with momentum v2 66.3/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.1/5 · 優秀
Dimension score 4.1/5
Dimension grade 優秀

Sub-items

pbPoints 0.4
pePoints 0.4
epsPoints 0.75
roePoints 0.6
debtPoints 0.4
marginPoints 0
turnoverUsdM 653.0956
volumePoints 0.5
revenuePoints 0
dividendPoints 0.5
marketCapPoints 0.5

資金流 — 9.2/20 · 較差
Dimension score 9.2/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 1.6
obvPoints 4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.KVUE
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 7.6/15 · 較差
Dimension score 7.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3

details

qqq

ma20 699.881
ma50 714.8264
name QQQ
close 700.07
points 1

spy

ma20 746.014
ma50 745.3184
name SPY
close 757.67
points 2
source twelvedata+fred
atrPct 2.343
atrPoints 3
cciPoints 1.6
vixPoints 0
marketTrendPoints 3

催化劑 — 6/20 · 較差
Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 5
catalystCount 1
catalystPoints 6

風險管理 — 7.4/10 · 良好
Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.343
turnoverUsdM 653.0956
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.KVUE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 18.1192

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.7
take_profit_price 20.0114
target_multiplier 1.9
technical_strength 1.78
take_profit_percent 5.3
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Consumer Staples
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.686
diversificationPoints 2

技術信號 — 19/30 · 一般
Dimension score 19/30
Dimension grade 一般

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 2.4
vcpPoints 2.7
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 2.7
vcp_reason 波幅收縮(12%→6.7%)；跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=N

vcp_metrics

up_days 5
vol_ref 20958570
down_days 4
vcp_ready true
above_ma50 true
avg_vol_10 17743620
avg_vol_20 18933465
avg_vol_30 20958570
range_pct_10 0.0671
range_pct_20 0.0815
range_pct_30 0.1197
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 0.8466
dist_to_20d_high 0.0556
down_shrink_days 3
breakout_level_20d 20.13
vcp_breakout_confirm false
contraction_ratio_10_30 0.5609
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 2/10 · 較差
Dimension score 2/10
Dimension grade 較差

Sub-items

sentiment

score 2

details

source finnhub_news_keyword_model
articleCount 5
negativeHits 0
positiveHits 0
sentimentScoreRaw 0

sentimentData

raw {"id":141021082,"url":"https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...","category":"company","datetime":1785028176,"headline":"Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"}, {"id":141021083,"url":"https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...","category":"company","datetime":1785024986,"headline":"Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"}, {"id":141016949,"url":"https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...","category":"company","datetime":1784992514,"headline":"Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"}, {"id":141010898,"url":"https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.","category":"company","datetime":1784925776,"headline":"KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"}, {"id":140888602,"url":"https://finnhub.io/api/news?id=ae52d316405d63f11ceec79e3056a8b6ca45ee006eb0757c47cc7ed85d650da6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"A federal appeals court has revived hundreds of lawsuits claiming that Tylenol use during pregnancy can increase the risk of autism and ADHD in children.","category":"company","datetime":1783962595,"headline":"KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits"}
raw_source {"id":141081692,"url":"https://finnhub.io/api/news?id=30ca5e3e530ef309da7cd41b174ea9ce0b24e11c3c7fe8f11fc4446e7e87381a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.","category":"company","datetime":1785518520,"headline":"Kenvue's Q2 Earnings Coming Up: Here's What Lies Ahead of the Stock"}, {"id":141078091,"url":"https://finnhub.io/api/news?id=b11e0ec14791d62bd98a0fff1b55701adb6ffc8624f51e2808ef2aa706ecc9a7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Church & Dwight (CHD) delivered earnings and revenue surprises of 0.00% and +1.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785499502,"headline":"Church & Dwight (CHD) Meets Q2 Earnings Estimates"}, {"id":141054091,"url":"https://finnhub.io/api/news?id=373e39fcc810642bfaa15338748453153259c83e0ab70ada8c058c2a28fd3eea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.","category":"company","datetime":1785335880,"headline":"Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook"}, {"id":141054092,"url":"https://finnhub.io/api/news?id=ab1fc595f65aff0d46ab053b8a8969d2a80149e3db8c932af7170e4eb3a1e791","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.","category":"company","datetime":1785335820,"headline":"Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty"}, {"id":141054399,"url":"https://finnhub.io/api/news?id=11fc9ce506f2a0bec926f7f22776292db527e98a7a1d96c20c82ef1fbc67c709","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.","category":"company","datetime":1785335760,"headline":"Kenvue Benefits From Consumer Health Trends and Margin Expansion"}, {"id":141052250,"url":"https://finnhub.io/api/news?id=ca0613044d5975b18d24b83dbc31cb9208aab497eb4eddd8565489ac141c261e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"SUMMIT, N.J., July 29, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.","category":"company","datetime":1785321900,"headline":"Kenvue Increases Quarterly Cash Dividend"}, {"id":141054400,"url":"https://finnhub.io/api/news?id=098c5e64880b72b99cc21958fa08d2e1d22ea28c5dc14ca98f4f6feb545f1571","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.","category":"company","datetime":1785314879,"headline":"What Are Wall Street Analysts' Target Price for Kenvue Stock?"}, {"id":141062384,"url":"https://finnhub.io/api/news?id=f15615f98ee3eec991d639a53cd40d9c6b274f10a2600a96a272fe05362e998d","image":"","source":"Benzinga","related":"KVUE","summary":"The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.","category":"company","datetime":1785307613,"headline":"Kenvue Increases Quarterly Dividend By 1.2% To $0.21 Per Share"}, {"id":141048146,"url":"https://finnhub.io/api/news?id=6bb82aad805c6a173e46be241afba15536fff4a89d414816e0eb8f701add24ee","image":"https://cdn.benzinga.com/files/images/story/2026/07/28/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536","source":"Benzinga","related":"KVUE","summary":"Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.","category":"company","datetime":1785233415,"headline":"Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest"}, {"id":141032930,"url":"https://finnhub.io/api/news?id=d870ed4d287c76d4d95b71bb84ebee653b237c80632e7985dae979065861a7d0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Black Monday wiped out 22% of the market in a single day, and most investors never saw it coming. A small group of companies not only survived that crash and every major meltdown since, but kept sending bigger checks to shareholders each time the panic peaked.","category":"company","datetime":1785154810,"headline":"5 Dividend Kings Continued to Pay and Raise Dividends Through Every Market Crash Since Black Monday"}, {"id":141028474,"url":"https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Dividend Kings beat SPY in June–July, reclaiming a YTD lead.","category":"company","datetime":1785093714,"headline":"Best Dividend Kings: July 2026"}, {"id":141021082,"url":"https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...","category":"company","datetime":1785028176,"headline":"Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"}, {"id":141021083,"url":"https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...","category":"company","datetime":1785024986,"headline":"Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"}, {"id":141016949,"url":"https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...","category":"company","datetime":1784992514,"headline":"Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"}, {"id":141010898,"url":"https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.","category":"company","datetime":1784925776,"headline":"KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"}, {"id":141009058,"url":"https://finnhub.io/api/news?id=7e3e1e371a19b270bdd4a967ba39ae684911a9e1c2808cce8205c9d0e7ab8f36","image":"","source":"Benzinga","related":"KVUE","summary":"TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief in a single dose.FDA-approved first and only OTC fixed‑dose","category":"company","datetime":1784901935,"headline":"FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen Sodium"}, {"id":141005278,"url":"https://finnhub.io/api/news?id=101d57aad953e5f98a330ef27d7ba5c285a1af9a27e27bfc8b6dd584d78b6aa2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]","category":"company","datetime":1784895731,"headline":"Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse"}, {"id":141009059,"url":"https://finnhub.io/api/news?id=9235f40a2e7b60e6c9500950aa681aa3c8213d91e5d2a5aba5de966cef163a69","image":"","source":"Benzinga","related":"KVUE","summary":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour","category":"company","datetime":1784890198,"headline":"FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain Relief"}, {"id":140992633,"url":"https://finnhub.io/api/news?id=c01b01860f8db055364a814e9521def9f2b01ae18e77753ca907627437ff1ed6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"SUMMIT, N.J., July 23, 2026--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.","category":"company","datetime":1784803500,"headline":"Kenvue to Announce Second Quarter 2026 Results on August 6, 2026"}, {"id":140973567,"url":"https://finnhub.io/api/news?id=76701072cf2fb47a5d34f32cec97c0f7678ae8fbee737c44fede042d9144ff06","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.","category":"company","datetime":1784630702,"headline":"What to Expect From Kenvue’s Q2 2026 Earnings Report"}, {"id":140977494,"url":"https://finnhub.io/api/news?id=fb71116732f86abd864fa15a78d1ae46e2abb100b8dfc9cf2fcc7154eaaf7241","image":"","source":"Benzinga","related":"KVUE","summary":"Barclays analyst Lauren Lieberman maintains Kenvue (NYSE:KVUE) with a Equal-Weight and raises the price target from $18 to $19.","category":"company","datetime":1784625659,"headline":"Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $19"}, {"id":140921287,"url":"https://finnhub.io/api/news?id=57e886de1abcf8ecce703b6f2c9a7064465a5bf14b826ec9a820e9cab6502850","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The report said Principal Financial had expressed interest earlier this year, but nothing came of the approach.","category":"company","datetime":1784214072,"headline":"VOYA Stock Hits Record High, Tops $100 For The First Time Ever – Report Says Voya Financial Has Been ‘Fielding’ Takeover Interest"}, {"id":140923473,"url":"https://finnhub.io/api/news?id=2aff097caeb37da10a25317dc060fb90d5cfe5e58134caffaf2a7e5ccb5ba2c4","image":"","source":"Benzinga","related":"KVUE","summary":"UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and raises the price target from $18 to $20.","category":"company","datetime":1784210326,"headline":"UBS Maintains Neutral on Kenvue, Raises Price Target to $20"}, {"id":140896909,"url":"https://finnhub.io/api/news?id=c6c17cc9cefc68d29a72aa162ba4f42e618f5f74356c274d7519a7146f1347c7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"While growth investors scrambled for cover in 2026, a quiet group of battle-tested income stocks started leaving the S&P 500 in the dust. Four Dividend Kings with decades of unbroken payouts are now posting returns that would make most momentum traders jealous, and Wall Street thinks they still have room to run.","category":"company","datetime":1784031603,"headline":"4 Dividend Kings Are Crushing the S&P 500 in 2026 and Still Have Big Upside Potential"}, {"id":140890161,"url":"https://finnhub.io/api/news?id=e25110c78ca2177615e41497f4272b141937d60a5e1b269003abf9d7270f7d7c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and","category":"company","datetime":1783971281,"headline":"Sector Update: Healthcare Stocks Advance Late Afternoon"}, {"id":140888922,"url":"https://finnhub.io/api/news?id=2688322ca92f5d3c1483ed79195c577694d4737e96ae3a9fb8e5d3ea5d3e792a","image":"https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp","source":"ChartMill","related":"KVUE","summary":"Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.","category":"company","datetime":1783965900,"headline":"Stay informed about the most active stocks in the S&P500 index on Monday's session."}, {"id":140888602,"url":"https://finnhub.io/api/news?id=ae52d316405d63f11ceec79e3056a8b6ca45ee006eb0757c47cc7ed85d650da6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"A federal appeals court has revived hundreds of lawsuits claiming that Tylenol use during pregnancy can increase the risk of autism and ADHD in children.","category":"company","datetime":1783962595,"headline":"KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits"}, {"id":140886787,"url":"https://finnhub.io/api/news?id=6540b5fb8052448f14bf5973c176f6a4ba2b01c2b79d32c66fb9dacef24aba89","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"All three major US stock indexes were down in late-morning trading Monday, as the US and Iran exchan","category":"company","datetime":1783958113,"headline":"Top Midday Stories: Trump Says US to Be Guardian of Hormuz Strait; Meta to Invest Over $50 Billion in Louisiana Data Center Expansion"}, {"id":140888395,"url":"https://finnhub.io/api/news?id=d50a547fa1d3601a3e58d3875738fe9d6e0ce21f3732b749f55851854f20a1a3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"(Bloomberg) -- A federal appeals court revived lawsuits that claim Kenvue Inc. hid alleged risks that Tylenol could cause autism in children whose mothers took the over-the-counter pain medication while pregnant, a controversy that’s roiled the medical community.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Embraces Australian Retirement System Backed by Larry FinkHormuz Route Open Despite Iran Declaration, Maritime Group SaysOpenAI Engineer’s ‘LOL’ Momen","category":"company","datetime":1783956006,"headline":"Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says"}, {"id":140887827,"url":"https://finnhub.io/api/news?id=9176067f3840c26dcec7c6b5260fbb2984fc13bd2b8a9a9e7ec21b5e65d20c3f","image":"","source":"Benzinga","related":"KVUE","summary":"-Reuters ","category":"company","datetime":1783939348,"headline":"U.S. Appeals Court Revives Private Lawsuits Linking Tylenol Painkiller To Autism, ADHD"}, {"id":140866193,"url":"https://finnhub.io/api/news?id=3f2e5e14bc617aaa8b286e72852f6297e0309a66b1b3633b444202ad357502b5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"DALLAS, July 10, 2026--Dean Omar Branham Shirley, LLP (DOBS), announced today that the Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who developed the deadly disease mesothelioma after decades of using Johnson & Johnson's Baby Powder. This product and other talc-based products have been found to be contaminated with asbestos.","category":"company","datetime":1783715400,"headline":"Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue"}, {"id":140832866,"url":"https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now","category":"company","datetime":1783444791,"headline":"3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"}
data_source finnhub_news_keyword_model
article_count 5
negative_hits 0
positive_hits 0
recomputed_at_score true
sentiment_score_raw 0
source_article_count 32
discarded_article_count 27
sentimentPoints 2

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.1 5/110 82% 4.1
資金流 9.2 20/110 46% 9.2
市場環境 7.6 15/110 50.67% 7.6
催化劑 6 20/110 30% 6
風險管理 7.4 10/110 74% 7.4
技術信號 19 30/110 63.33% 19
情緒分析 2 10/110 20% 2

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 11/50
ret_5d -0.0241
max_score 50
max_total 50
raw_total 11
vcp_bonus 0
vol_ratio 1.8145
ret_points 0
vol_points 6
range_ratio 2.2542
volat_points 4
day_range_pct 0.0479
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.343
turnoverUsdM 653.0956
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.KVUE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 18.1192

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.7
take_profit_price 20.0114
target_multiplier 1.9
technical_strength 1.78
take_profit_percent 5.3
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Consumer Staples
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.686
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.1/5分
資金流分析總分: 9.2/20分
市場環境分析總分: 7.6/15分
催化劑分析: 6/20分
風險管理總分: 7.4/10分
技術信號分析總分: 19/30分
情緒分析: 2/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 0.4454
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.34
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -20.46
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0573
kdj
d 52.93
j 20.42
k 42.09
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 42.64
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 40638130
recentSlope 1125683
previousSlope -10943380
rsi
value 55.02
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 18.8178
position SAR喺價下
distancePct 1.01
previousTrend 上升
ma50
value 18.5624
macd
macd 0.1806
trend 中性偏多
signal 0.2263
histogram -0.0458
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 19.2485
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.77
score 6
avgVolume 19393269
currentVolume 34355370
derived
ma20 19.217
ma50 18.5624
prevClose 19.24
avgVolume10 19956937
avgVolume20 19393269
changePercent -1.2
avgVolumeForScore 19393269
ma_cross
ma20 19.217
ma50 18.5624
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 19.2445
prevMa50 18.5286
spreadPct 3.53
isVolumeBreakout true
bollinger
lower 18.602
upper 19.832
position 中間
rsi_short
value 39.53
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.77

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.342977380326144,
        "turnoverUsdM": 653.0955837,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.KVUE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 18.1192,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.7,
      "take_profit_price": 20.0114,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5.3
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Consumer Staples",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.685954760652288,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 66.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 55.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 19.217,
    "ma50": 18.5624,
    "close": 19.01,
    "prevClose": 19.24,
    "avgVolume20": 19393269,
    "volumeRatio": 1.77,
    "changePercent": -1.2
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": -0.024127310061601626,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 1.8145315714793884,
      "ret_points": 0,
      "vol_points": 6,
      "range_ratio": 2.254172510673117,
      "volat_points": 4,
      "day_range_pct": 0.047869542346133616,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 66.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.1,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 82,
        "contribution": 4.1
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 7.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 50.67,
        "contribution": 7.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 19,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63.33,
        "contribution": 19
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 55.3,
    "details": [
      "基本面分析總分: 4.1/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 7.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 19/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.1,
      "資金流": 9.2,
      "市場環境": 7.6,
      "情緒分析": 2,
      "技術信號": 19,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.6,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 653.0955837,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.KVUE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 699.88099675,
                "ma50": 714.8264005399999,
                "name": "QQQ",
                "close": 700.070007,
                "points": 1
              },
              "spy": {
                "ma20": 746.0140036500002,
                "ma50": 745.31840316,
                "name": "SPY",
                "close": 757.66998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.342977380326144,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141021082,
                "url": "https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...",
                "category": "company",
                "datetime": 1785028176,
                "headline": "Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"
              },
              {
                "id": 141021083,
                "url": "https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...",
                "category": "company",
                "datetime": 1785024986,
                "headline": "Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"
              },
              {
                "id": 141016949,
                "url": "https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...",
                "category": "company",
                "datetime": 1784992514,
                "headline": "Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"
              },
              {
                "id": 141010898,
                "url": "https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.",
                "category": "company",
                "datetime": 1784925776,
                "headline": "KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"
              },
              {
                "id": 140888602,
                "url": "https://finnhub.io/api/news?id=ae52d316405d63f11ceec79e3056a8b6ca45ee006eb0757c47cc7ed85d650da6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "A federal appeals court has revived hundreds of lawsuits claiming that Tylenol use during pregnancy can increase the risk of autism and ADHD in children.",
                "category": "company",
                "datetime": 1783962595,
                "headline": "KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits"
              }
            ],
            "raw_source": [
              {
                "id": 141081692,
                "url": "https://finnhub.io/api/news?id=30ca5e3e530ef309da7cd41b174ea9ce0b24e11c3c7fe8f11fc4446e7e87381a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.",
                "category": "company",
                "datetime": 1785518520,
                "headline": "Kenvue's Q2 Earnings Coming Up: Here's What Lies Ahead of the Stock"
              },
              {
                "id": 141078091,
                "url": "https://finnhub.io/api/news?id=b11e0ec14791d62bd98a0fff1b55701adb6ffc8624f51e2808ef2aa706ecc9a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Church & Dwight (CHD) delivered earnings and revenue surprises of 0.00% and +1.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499502,
                "headline": "Church & Dwight (CHD) Meets Q2 Earnings Estimates"
              },
              {
                "id": 141054091,
                "url": "https://finnhub.io/api/news?id=373e39fcc810642bfaa15338748453153259c83e0ab70ada8c058c2a28fd3eea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.",
                "category": "company",
                "datetime": 1785335880,
                "headline": "Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook"
              },
              {
                "id": 141054092,
                "url": "https://finnhub.io/api/news?id=ab1fc595f65aff0d46ab053b8a8969d2a80149e3db8c932af7170e4eb3a1e791",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.",
                "category": "company",
                "datetime": 1785335820,
                "headline": "Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty"
              },
              {
                "id": 141054399,
                "url": "https://finnhub.io/api/news?id=11fc9ce506f2a0bec926f7f22776292db527e98a7a1d96c20c82ef1fbc67c709",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.",
                "category": "company",
                "datetime": 1785335760,
                "headline": "Kenvue Benefits From Consumer Health Trends and Margin Expansion"
              },
              {
                "id": 141052250,
                "url": "https://finnhub.io/api/news?id=ca0613044d5975b18d24b83dbc31cb9208aab497eb4eddd8565489ac141c261e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., July 29, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.",
                "category": "company",
                "datetime": 1785321900,
                "headline": "Kenvue Increases Quarterly Cash Dividend"
              },
              {
                "id": 141054400,
                "url": "https://finnhub.io/api/news?id=098c5e64880b72b99cc21958fa08d2e1d22ea28c5dc14ca98f4f6feb545f1571",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.",
                "category": "company",
                "datetime": 1785314879,
                "headline": "What Are Wall Street Analysts' Target Price for Kenvue Stock?"
              },
              {
                "id": 141062384,
                "url": "https://finnhub.io/api/news?id=f15615f98ee3eec991d639a53cd40d9c6b274f10a2600a96a272fe05362e998d",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.",
                "category": "company",
                "datetime": 1785307613,
                "headline": "Kenvue Increases Quarterly Dividend By 1.2% To $0.21 Per Share"
              },
              {
                "id": 141048146,
                "url": "https://finnhub.io/api/news?id=6bb82aad805c6a173e46be241afba15536fff4a89d414816e0eb8f701add24ee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "Johnson &amp; Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.",
                "category": "company",
                "datetime": 1785233415,
                "headline": "Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest"
              },
              {
                "id": 141032930,
                "url": "https://finnhub.io/api/news?id=d870ed4d287c76d4d95b71bb84ebee653b237c80632e7985dae979065861a7d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Black Monday wiped out 22% of the market in a single day, and most investors never saw it coming. A small group of companies not only survived that crash and every major meltdown since, but kept sending bigger checks to shareholders each time the panic peaked.",
                "category": "company",
                "datetime": 1785154810,
                "headline": "5 Dividend Kings Continued to Pay and Raise Dividends Through Every Market Crash Since Black Monday"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141021082,
                "url": "https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...",
                "category": "company",
                "datetime": 1785028176,
                "headline": "Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"
              },
              {
                "id": 141021083,
                "url": "https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...",
                "category": "company",
                "datetime": 1785024986,
                "headline": "Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"
              },
              {
                "id": 141016949,
                "url": "https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...",
                "category": "company",
                "datetime": 1784992514,
                "headline": "Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"
              },
              {
                "id": 141010898,
                "url": "https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.",
                "category": "company",
                "datetime": 1784925776,
                "headline": "KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"
              },
              {
                "id": 141009058,
                "url": "https://finnhub.io/api/news?id=7e3e1e371a19b270bdd4a967ba39ae684911a9e1c2808cce8205c9d0e7ab8f36",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief in a single dose.FDA-approved first and only OTC fixed‑dose",
                "category": "company",
                "datetime": 1784901935,
                "headline": "FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen Sodium"
              },
              {
                "id": 141005278,
                "url": "https://finnhub.io/api/news?id=101d57aad953e5f98a330ef27d7ba5c285a1af9a27e27bfc8b6dd584d78b6aa2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]",
                "category": "company",
                "datetime": 1784895731,
                "headline": "Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse"
              },
              {
                "id": 141009059,
                "url": "https://finnhub.io/api/news?id=9235f40a2e7b60e6c9500950aa681aa3c8213d91e5d2a5aba5de966cef163a69",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour",
                "category": "company",
                "datetime": 1784890198,
                "headline": "FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain Relief"
              },
              {
                "id": 140992633,
                "url": "https://finnhub.io/api/news?id=c01b01860f8db055364a814e9521def9f2b01ae18e77753ca907627437ff1ed6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., July 23, 2026--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.",
                "category": "company",
                "datetime": 1784803500,
                "headline": "Kenvue to Announce Second Quarter 2026 Results on August 6, 2026"
              },
              {
                "id": 140973567,
                "url": "https://finnhub.io/api/news?id=76701072cf2fb47a5d34f32cec97c0f7678ae8fbee737c44fede042d9144ff06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.",
                "category": "company",
                "datetime": 1784630702,
                "headline": "What to Expect From Kenvue’s Q2 2026 Earnings Report"
              },
              {
                "id": 140977494,
                "url": "https://finnhub.io/api/news?id=fb71116732f86abd864fa15a78d1ae46e2abb100b8dfc9cf2fcc7154eaaf7241",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "Barclays  analyst Lauren Lieberman   maintains Kenvue (NYSE:KVUE) with a Equal-Weight and raises the price target from $18 to $19.",
                "category": "company",
                "datetime": 1784625659,
                "headline": "Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $19"
              },
              {
                "id": 140921287,
                "url": "https://finnhub.io/api/news?id=57e886de1abcf8ecce703b6f2c9a7064465a5bf14b826ec9a820e9cab6502850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The report said Principal Financial had expressed interest earlier this year, but nothing came of the approach.",
                "category": "company",
                "datetime": 1784214072,
                "headline": "VOYA Stock Hits Record High, Tops $100 For The First Time Ever – Report Says Voya Financial Has Been ‘Fielding’ Takeover Interest"
              },
              {
                "id": 140923473,
                "url": "https://finnhub.io/api/news?id=2aff097caeb37da10a25317dc060fb90d5cfe5e58134caffaf2a7e5ccb5ba2c4",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "UBS  analyst Peter Grom   maintains Kenvue (NYSE:KVUE) with a Neutral and raises the price target from $18 to $20.",
                "category": "company",
                "datetime": 1784210326,
                "headline": "UBS Maintains Neutral on Kenvue, Raises Price Target to $20"
              },
              {
                "id": 140896909,
                "url": "https://finnhub.io/api/news?id=c6c17cc9cefc68d29a72aa162ba4f42e618f5f74356c274d7519a7146f1347c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "While growth investors scrambled for cover in 2026, a quiet group of battle-tested income stocks started leaving the S&P 500 in the dust. Four Dividend Kings with decades of unbroken payouts are now posting returns that would make most momentum traders jealous, and Wall Street thinks they still have room to run.",
                "category": "company",
                "datetime": 1784031603,
                "headline": "4 Dividend Kings Are Crushing the S&P 500 in 2026 and Still Have Big Upside Potential"
              },
              {
                "id": 140890161,
                "url": "https://finnhub.io/api/news?id=e25110c78ca2177615e41497f4272b141937d60a5e1b269003abf9d7270f7d7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and",
                "category": "company",
                "datetime": 1783971281,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140888922,
                "url": "https://finnhub.io/api/news?id=2688322ca92f5d3c1483ed79195c577694d4737e96ae3a9fb8e5d3ea5d3e792a",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1783965900,
                "headline": "Stay informed about the most active stocks in the S&P500 index on Monday's session."
              },
              {
                "id": 140888602,
                "url": "https://finnhub.io/api/news?id=ae52d316405d63f11ceec79e3056a8b6ca45ee006eb0757c47cc7ed85d650da6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "A federal appeals court has revived hundreds of lawsuits claiming that Tylenol use during pregnancy can increase the risk of autism and ADHD in children.",
                "category": "company",
                "datetime": 1783962595,
                "headline": "KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits"
              },
              {
                "id": 140886787,
                "url": "https://finnhub.io/api/news?id=6540b5fb8052448f14bf5973c176f6a4ba2b01c2b79d32c66fb9dacef24aba89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "All three major US stock indexes were down in late-morning trading Monday, as the US and Iran exchan",
                "category": "company",
                "datetime": 1783958113,
                "headline": "Top Midday Stories: Trump Says US to Be Guardian of Hormuz Strait; Meta to Invest Over $50 Billion in Louisiana Data Center Expansion"
              },
              {
                "id": 140888395,
                "url": "https://finnhub.io/api/news?id=d50a547fa1d3601a3e58d3875738fe9d6e0ce21f3732b749f55851854f20a1a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "(Bloomberg) -- A federal appeals court revived lawsuits that claim Kenvue Inc. hid alleged risks that Tylenol could cause autism in children whose mothers took the over-the-counter pain medication while pregnant, a controversy that’s roiled the medical community.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Embraces Australian Retirement System Backed by Larry FinkHormuz Route Open Despite Iran Declaration, Maritime Group SaysOpenAI Engineer’s ‘LOL’ Momen",
                "category": "company",
                "datetime": 1783956006,
                "headline": "Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says"
              },
              {
                "id": 140887827,
                "url": "https://finnhub.io/api/news?id=9176067f3840c26dcec7c6b5260fbb2984fc13bd2b8a9a9e7ec21b5e65d20c3f",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "-Reuters ",
                "category": "company",
                "datetime": 1783939348,
                "headline": "U.S. Appeals Court Revives Private Lawsuits Linking Tylenol Painkiller To Autism, ADHD"
              },
              {
                "id": 140866193,
                "url": "https://finnhub.io/api/news?id=3f2e5e14bc617aaa8b286e72852f6297e0309a66b1b3633b444202ad357502b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "DALLAS, July 10, 2026--Dean Omar Branham Shirley, LLP (DOBS), announced today that the Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who developed the deadly disease mesothelioma after decades of using Johnson & Johnson's Baby Powder. This product and other talc-based products have been found to be contaminated with asbestos.",
                "category": "company",
                "datetime": 1783715400,
                "headline": "Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue"
              },
              {
                "id": 140832866,
                "url": "https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now",
                "category": "company",
                "datetime": 1783444791,
                "headline": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 5,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 32,
            "discarded_article_count": 27
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(12%→6.7%)；跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 20958570,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 17743620,
              "avg_vol_20": 18933465,
              "avg_vol_30": 20958570,
              "range_pct_10": 0.06712256706996315,
              "range_pct_20": 0.08153603366649136,
              "range_pct_30": 0.11967385586533395,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8466045154798252,
              "dist_to_20d_high": 0.05563835072031781,
              "down_shrink_days": 3,
              "breakout_level_20d": 20.13,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5608791208791211
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.342977380326144,
              "turnoverUsdM": 653.0955837,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.KVUE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 18.1192,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.7,
            "take_profit_price": 20.0114,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5.3
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Consumer Staples",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.685954760652288,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.KVUE",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.4454,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.34
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -20.46
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0573
    },
    "kdj": {
      "d": 52.93,
      "j": 20.42,
      "k": 42.09,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 42.64
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 40638130,
      "recentSlope": 1125683,
      "previousSlope": -10943380
    },
    "rsi": 55.02,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 18.8178,
      "position": "SAR喺價下",
      "distancePct": 1.01,
      "previousTrend": "上升"
    },
    "ma50": 18.5624,
    "macd": {
      "macd": 0.18058316634396832,
      "trend": "中性偏多",
      "signal": 0.22634361892513322,
      "histogram": -0.0457604525811649
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 19.2485,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.77,
      "score": 6,
      "avgVolume": 19393269,
      "currentVolume": 34355370
    },
    "derived": {
      "ma20": 19.217,
      "ma50": 18.5624,
      "prevClose": 19.24,
      "avgVolume10": 19956937,
      "avgVolume20": 19393269,
      "changePercent": -1.2,
      "avgVolumeForScore": 19393269
    },
    "ma_cross": {
      "ma20": 19.217,
      "ma50": 18.5624,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 19.2445,
      "prevMa50": 18.5286,
      "spreadPct": 3.53,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 18.602,
      "upper": 19.832,
      "position": "中間"
    },
    "rsi_short": 39.53,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.77
    }
  }
}

Raw metrics JSON

 
{
  "close": 19.01,
  "volume": 34355370,
  "changePercent": -1.2
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.